Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized Scleroderma
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The DupiMorph study evaluates the efficacy of Dupilumab in localized scleroderma patients.
Dupilumab is approved in the US and EU for the treatment of moderate/severe atopic dermatitis
and since 2018 in the US for severe asthma therapy.